基于双膦配体的受体靶向肽偶联物可实现用于前列腺癌的99mTc与188Re诊疗一体剂制备
研究将两种双膦-二肽生物偶联物DP1-PSMAt与DP2-PSMAt制成药盒,分别用99mTc和188Re进行放射性标记,并在前列腺癌细胞及小鼠异种移植模型中评价。结果显示每种99mTc/188Re放射性示踪剂对均表现出几乎相同的生物学行为,肿瘤摄取高(注射后2小时为每克18-30%注射剂量),非靶器官滞留低、血液清除快、主要经肾排泄。作者认为这类基于发生器的诊疗一体剂有望在常规无法获得177Lu放射性药物或PET/CT设施的医疗环境中提供PSMA靶向诊断成像和全身放疗的益处。
要点
- DP1-PSMAt与DP2-PSMAt均可通过药盒法高效标记99mTc和188Re,得到同构化合物M-DP1-PSMAt与M-DP2-PSMAt。
- 所有99mTc/188Re放射性示踪剂在PSMA表达前列腺癌细胞中呈特异性摄取,在PSMA不表达或PSMA摄取被阻断的细胞中摄取可忽略。
- M-DP1-PSMAt与M-DP2-PSMAt肿瘤摄取高(注射后2小时为每克18-30%注射剂量),非靶器官滞留低、血液清除快、主要经肾排泄。
核心结论
- 作者制备并开发了新型同构PSMA靶向99mTc/188Re诊疗一体剂对,每种99mTc/188Re放射性示踪剂对在这些实验中表现出几乎相同的生物学行为。
- 作者认为这些基于发生器的诊疗一体剂有潜力在常规无法获得177Lu放射性药物或PET/CT设施的医疗环境中提供PSMA靶向诊断成像和全身放疗的益处。
研究设计与样本
- 研究将两种双膦-二肽生物偶联物DP1-PSMAt与DP2-PSMAt制成药盒,用于99mTc和188Re放射性标记。
- 所得放射性示踪剂在前列腺癌细胞中体外研究,并在小鼠异种移植模型中体内研究,以评估每对99mTc/188Re药物的摄取与生物分布相似性。
主要发现
- DP1-PSMAt与DP2-PSMAt均可通过药盒法高效标记99mTc和188Re,得到同构化合物M-DP1-PSMAt与M-DP2-PSMAt(M = [99mTc]Tc、[188Re]Re)。
- 所有99mTc/188Re放射性示踪剂在PSMA表达前列腺癌细胞中呈特异性摄取,在PSMA不表达或PSMA摄取被阻断的前列腺癌细胞中摄取可忽略。
- M-DP1-PSMAt与M-DP2-PSMAt肿瘤摄取高(注射后2小时为每克18-30%注射剂量),非靶器官滞留低、血液清除快、主要经肾排泄。
- 每对99mTc/188Re放射性示踪剂在这些实验中表现出几乎相同的生物学行为。
临床怎么用
- 作者认为这些基于发生器的诊疗一体剂有潜力在常规无法获得177Lu放射性药物或PET/CT设施的医疗环境中提供PSMA靶向诊断成像和全身放疗的益处。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Benchtop 99Mo/99mTc and 188W/188Re generators enable economical production of molecular theranostic 99mTc and 188Re radiopharmaceuticals, provided that simple, kit-based chemistry exists to radiolabel targeting vectors with these radionuclides. We have previously described a diphosphine platform that efficiently incorporates 99mTc into receptor-targeted peptides. Here, we report its application to label a prostate-specific membrane antigen (PSMA)-targeted peptide with 99mTc and 188Re for diagnostic imaging and systemic radiotherapy of prostate cancer. Methods: Two diphosphine-dipeptide bioconjugates, DP1-PSMAt and DP2-PSMAt, were formulated into kits for radiolabeling with 99mTc and 188Re. The resulting radiotracers were studied in vitro, in prostate cancer cells, and in vivo in mouse xenograft models, to assess similarity of uptake and biodistribution for each 99mTc/188Re pair of agents. Results: Both DP1-PSMAt and DP2-PSMAt could be efficiently radiolabeled with 99mTc and 188Re using kit-based methods to furnish the isostructural compounds M-DP1-PSMAt and M-DP2-PSMAt (M = [99mTc]Tc, [188Re]Re). All 99mTc/188Re radiotracers demonstrated specific uptake in PSMA-expressing prostate cancer cells, with negligible uptake in prostate cancer cells that did not express PSMA or in which PSMA uptake was blocked. M-DP1-PSMAt and M-DP2-PSMAt also exhibited high tumor uptake (18-30 percentage injected dose per gram at 2 h after injection), low retention in nontarget organs, fast blood clearance, and excretion predominantly via a renal pathway. Importantly, each pair of 99mTc/188Re radiotracers showed near-identical biologic behavior in these experiments. Conclusion: We have prepared and developed novel pairs of isostructural PSMA-targeting 99mTc/188Re theranostic agents. These generator-based theranostic agents have potential to provide access to the benefits of PSMA-targeted diagnostic imaging and systemic radiotherapy in health care settings that do not routinely have access to either reactor-produced 177Lu radiopharmaceuticals or PET/CT infrastructure.
引用
- Pham TT, Hungnes IN, Rivas C, et al. Receptor-Targeted Peptide Conjugates Based on Diphosphines Enable Preparation of 99mTc and 188Re Theranostic Agents for Prostate Cancer. J Nucl Med. 2024. PMID: 38844360. doi:10.2967/jnumed.124.267450
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。